Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - CEL SCI CORP | cvm_8k.htm |
EXHIBIT 99
NEWS
RELEASE
|
8229
Boone Boulevard, Suite 802
Vienna,
VA 22182. USA
Telephone
(703) 506-9460
www.cel-sci.com
|
COMPANY
CONTACT:
Gavin
de Windt
CEL-SCI
Corporation
(703)
506-9460
|
CEL-SCI RECEIVES ABOUT $8 MILLION FROM WARRANT
EXERCISES
Vienna, VA, October 23, 2018 - CEL-SCI Corporation
(NYSE American: CVM)
announced today it has received just under $8 million through the
exercise of warrants to purchase shares of the Company's common
stock during the past 3 months. As of October 22, 2018, CEL-SCI had
28,271,615 outstanding shares of common stock.
"We
have raised $20 million this year as we are nearing the date for
the final data readout on our pivotal, global Phase 3 study in head
and neck cancer," stated CEL-SCI's Chief Executive Officer Geert
Kersten.
About CEL-SCI Corporation
CEL-SCI
believes that boosting a patient's immune system while it is still
intact should provide the greatest possible impact on survival.
Therefore, in the Phase 3 study CEL-SCI treats patients who are
newly diagnosed with advanced primary squamous cell carcinoma of
the head and neck with Multikine* first, BEFORE they receive
surgery, radiation and/or chemotherapy. This approach is unique.
Most other cancer immunotherapies are administered only after
conventional therapies have been tried and/or failed. Multikine
(Leukocyte Interleukin, Injection), has received Orphan Drug
designation from the FDA for the neoadjuvant therapy in patients
with squamous cell carcinoma (cancer) of the head and
neck.
CEL-SCI's
Phase 3 study is the largest Phase 3 study in the world for the
treatment of head and neck cancer. Per the study's protocol, newly
diagnosed patients with advanced primary squamous cell carcinoma
are treated with the Multikine treatment regimen for 3 weeks prior
to the Standard of Care (SOC) which involves surgery, chemotherapy
and/or radiation. Multikine is designed to help the immune system
"see" the tumor at a time when the immune system is still
relatively intact and thereby better able to mount an attack on the
tumor. The aim of treatment with Multikine is to boost the body's
immune system prior to SOC.
The
Company's LEAPS technology is currently being developed as a
therapeutic vaccine for rheumatoid arthritis and is supported by
grants from the National Institutes of Health. The Company has
operations in Vienna, Virginia, and in/near Baltimore,
Maryland.
Forward-Looking Statements
This
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
When used in this press release, the words "intends," "believes,"
"anticipated," "plans" and "expects," and similar expressions, are
intended to identify forward-looking statements. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Such statements
include, but are not limited to, statements about the terms,
expected proceeds, use of proceeds and closing of the offering.
Factors that could cause or contribute to such differences include,
an inability to duplicate the clinical results demonstrated in
clinical studies, timely development of any potential products that
can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary
capital and the risk factors set forth from time to time in
CEL-SCI's filings with the Securities and Exchange Commission,
including but not limited to its report on Form 10-K for the year
ended September 30, 2017. The Company undertakes no obligation to
publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in
progress.